

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HighTide Therapeutics, Inc.

君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 29, 2026

Reference is made to the circular of HighTide Therapeutics, Inc. (the “**Company**”) dated June 2, 2026 (the “**Circular**”) and the notice of annual general meeting of the Company (the “**AGM**”) dated June 2, 2026. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

At the AGM held at meeting room 24, 2/F, Building 10W, 10 Science Park West Avenue, Hong Kong Science Park, New Territories, Hong Kong on Monday, June 29, 2026 at 10:00 a.m., poll voting was demanded by the chairwoman of the AGM for voting on all the proposed resolutions, as set out in the notice of AGM dated June 2, 2026.

The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		No. of votes (Approximate %)		Total votes
		For	Against	
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the “ Directors ”) and auditor of the Company for the year ended December 31, 2025.	162,500,992 (100.000000%)	0 (0.000000%)	162,500,992
2.	(A) To re-elect the following retiring Directors:			
	(i) Dr. LIU Liping as an executive Director of the Company;	162,500,992 (100.000000%)	0 (0.000000%)	162,500,992
	(ii) Mr. MA Lixiong as a non-executive Director of the Company;	162,500,992 (100.000000%)	0 (0.000000%)	162,500,992
	(iii) Mr. HUNG Tak Wai as an independent non-executive Director of the Company; and	162,500,992 (100.000000%)	0 (0.000000%)	162,500,992

ORDINARY RESOLUTIONS		No. of votes (Approximate %)		Total votes
		For	Against	
	(iv) Mr. CHEN Mingyu as an independent non-executive Director of the Company.	162,500,992 (100.000000%)	0 (0.000000%)	162,500,992
	(B) To authorize the board of Directors (the “ Board ”) to fix the remuneration of the Directors.	162,500,992 (100.000000%)	0 (0.000000%)	162,500,992
3.	To re-appoint Moore CPA Limited as auditor of the Company and authorize the Board to fix their remuneration.	162,500,992 (100.000000%)	0 (0.000000%)	162,500,992
4.	(A) To give a general mandate to the directors of the Company to allot, issue and deal with additional shares (including a sale or transfer of treasury shares out of treasury) not exceeding 20% of the number of shares of the Company in issue (excluding treasury shares) as at the date of this resolution.	162,168,492 (99.795386%)	332,500 (0.204614%)	162,500,992
	(B) To give a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the number of shares of the Company in issue (excluding treasury shares) as at the date of this resolution.	144,574,222 (88.968209%)	17,926,770 (11.031791%)	162,500,992
	(C) To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 4(A) by adding to the number of shares of the Company repurchased under ordinary resolution no. 4(B).	144,241,722 (88.763595%)	18,259,270 (11.236405%)	162,500,992

As at the date of the AGM, the total number of issued shares of the Company was 571,325,668 Shares and the Company held no treasury shares (as defined under the Listing Rules). As at the date of the AGM, (i) Shares underlying the unexercised options granted under the 2020 ESOP Platform (i.e. 33,022,195 Shares); and (ii) Shares underlying the unexercised options granted under the 2023 ESOP Platform (i.e. 1,800,000 Shares), abstained from voting at the AGM. Accordingly, the total number of Shares entitling the Shareholders to attend and vote for or against the resolutions proposed at the AGM was 536,503,473 Shares, representing approximately 93.91% of the total number of issued Shares as at the date of the AGM. Save as disclosed above, to the best knowledge, information and belief of the Directors: (1) no other Shareholders were required under the Listing Rules to abstain from voting on any of the resolutions; (2) there were no Shares entitling the holders to attend and abstain from voting in favor of any of the resolutions under Rule 13.40 of the Listing Rules; and (3) there was no restriction on any Shareholders to cast votes on any of the resolutions proposed at the AGM and no other Shareholders have indicated in the Circular that they intend to vote against or to abstain from voting on any of the resolutions.

As more than 50% of votes were cast in favor of each of the above ordinary resolutions numbered 1 to 4, all of the above ordinary resolutions were duly passed as ordinary resolutions of the Company.

Please refer to the Circular for the full text of the abovementioned resolutions.

Dr. LIU Liping, Chairwoman of the Board and chief executive officer of the Company, acted as the chairwoman of the AGM and presided over the AGM. Our Directors Dr. LIU Liping, Ms. YU Meng, Dr. ZHU Xun, Mr. MA Lixiong, Dr. LI Jin and Mr. CHEN Mingyu attended the AGM in person or by electronic means. The other Directors did not attend the AGM due to their other business commitments.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, June 29, 2026

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Dr. LI Jin, Mr. HUNG Tak Wai and Mr. CHEN Mingyu as independent non-executive Directors.